Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

@article{Betts2018TargetingJR,
  title={Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.},
  author={Brian Betts and David Bastian and Supinya Iamsawat and Hung Nguyen and Jessica Lauren Heinrichs and Yongxia Wu and Anusara Daenthanasanmak and Anandharaman Veerapathran and Alison O'Mahony and Kelly Walton and Jordan Reff and Pedro Horna and Elizabeth M. Sagatys and Marie Catherine Lee and Jack W. Singer and Yingjun Chang and Chen Liu and Joseph A Pidala and Claudio M. Anasetti and Xue-zhong Yu},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2018},
  volume={115 7},
  pages={
          1582-1587
        }
}
Janus kinase 2 (JAK2) signal transduction is a critical mediator of the immune response. JAK2 is implicated in the onset of graft-versus-host disease (GVHD), which is a significant cause of transplant-related mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Transfer of JAK2-/- donor T cells to allogeneic recipients leads to attenuated GVHD yet maintains graft-versus-leukemia. Th1 differentiation among JAK2-/- T cells is significantly decreased compared with wild-type… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Similar Papers

Loading similar papers…